Company Profile
Gilead Sciences Stock Price, News & Analysis
- Ticker:
- GILD
- Exchange:
- NASDAQ
- Sector:
- Infectious Disease, Biopharma, Nucleic Acid Drugs, CAR-T Therapy, Gene Therapy
- Location:
- United States
Stock performance
130.52 USD (+0.94%)
Close
Last updated: July 27, 2026
158B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, GILD closed up 0.94% at $130.52. No new same-company headline was identified in the current news window.
Company overview
Business overview
Gilead Sciences is a biopharmaceutical company with deep roots in antiviral therapy and growing exposure to oncology and inflammation. Its story has evolved from a legacy antiviral leader into a broader commercial and pipeline platform.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Gilead has a global commercial footprint with major exposure to the U.S. and Europe. It sits in large-cap biopharma with a strong commercial base.
Business Model Characteristics
The company generates revenue through branded therapies, lifecycle management, and pipeline reinvestment across multiple therapeutic areas. Investors focus on HIV, hepatitis, oncology, and the ability to keep replacing mature revenue streams with new assets.
Position Within the Biotechnology Landscape
Gilead is a mature large-cap biotech company with enough pipeline depth to retain catalyst sensitivity. It is less binary than development-stage names, but major launch, approval, and partnership updates still matter.
Future catalysts
Gilead’s biggest near-term catalyst is lenacapavir, especially prevention and filing progress, alongside Trodelvy and the oncology franchise. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Gilead Sciences (GILD)?
Gilead Sciences (GILD) most recently closed at 130.52 USD, a +0.94% move versus the previous session.
What is the market cap of Gilead Sciences (GILD)?
Gilead Sciences currently has a market capitalization of 158B USD on BioPharmSignal.
What does Gilead Sciences do?
Gilead Sciences is a biopharmaceutical company with deep roots in antiviral therapy and growing exposure to oncology and inflammation. Its story has evolved from a legacy antiviral leader into a broader commercial and pipeline platform.
On which exchange is GILD stock listed?
Gilead Sciences (GILD) is associated with NASDAQ, United States, Infectious Disease, Biopharma, Nucleic Acid Drugs, CAR-T Therapy, Gene Therapy.
What is lenacapavir?
Gilead’s biggest near-term catalyst is lenacapavir, especially prevention and filing progress, alongside Trodelvy and the oncology franchise.
Which conditions is Gilead Sciences targeting with lenacapavir?
Gilead Sciences is associated with oncology, inflammatory disease based on its company overview and current catalyst commentary.
How does Gilead Sciences describe recent progress with lenacapavir?
Gilead’s biggest near-term catalyst is lenacapavir, especially prevention and filing progress, alongside Trodelvy and the oncology franchise.
What is Gilead?
Gilead Sciences is a biopharmaceutical company with deep roots in antiviral therapy and growing exposure to oncology and inflammation.